Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

IMGN853

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Grade 3 endometrioid and uterine serous carcinomas (USC) account for the vast majority of endometrial cancer deaths. The purpose… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2017
Highly Cited
2017
Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an… Expand
Is this relevant?
2017
2017
BACKGROUND Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate that selectively targets folate receptor α (FRα). In… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2017
2017
5553Background: FORWARD II is a phase 1b study of the FRα-targeting ADC, mirvetuximab soravtansine (IMGN853), in combination with… Expand
Is this relevant?
2017
2017
5547Background: The early clinical evaluation of mirvetuximab soravtansine (IMGN853), an ADC that comprises a FRα-binding… Expand
Is this relevant?
2016
2016
Elevated folate receptor alpha (FRα) expression is characteristic of epithelial ovarian cancer (EOC), thus establishing this… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
A majority of ovarian and non–small cell lung adenocarcinoma cancers overexpress folate receptor α (FRα). Here, we report the… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2015
2015
5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-binding antibody conjugated with… Expand
Is this relevant?
2014
2014
5571 Background: IMGN853 is a FRα-targeting ADC that comprises a FRa-binding antibody conjugated with the potent maytansinoid… Expand
Is this relevant?
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL IMGN853 (M9346A-sulfo-SPDB-DM4) is an antibody drug… Expand
Is this relevant?